Ambrisentan is indicated for:
Population group: both men and women, only adults (18 years old or older)
Ambrisentan is indicated for treatment of pulmonary arterial hypertension (PAH) in adult patients of WHO Functional Class (FC) II to III, including use in combination treatment. Efficacy has been shown in idiopathic PAH (IPAH) and in PAH associated with connective tissue disease.
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Ambrisentan is contraindicated in the following cases: